State of FAIRness in ESFRI Projects
暂无分享,去创建一个
Petr Holub | Dieter Van Uytvanck | Peter Wittenburg | Franciska de Jong | Hannes Thiemann | Keith G. Jeffery | Massimo Cocco | Ari Asmi | Michael Lautenschlager | Margareta Hellström
[1] S. Morrison,et al. Time to do something about reproducibility , 2014, eLife.
[2] C. Begley,et al. Drug development: Raise standards for preclinical cancer research , 2012, Nature.
[3] Petr Holub,et al. Toward Global Biobank Integration by Implementation of the Minimum Information About BIobank Data Sharing (MIABIS 2.0 Core). , 2016, Biopreservation and biobanking.
[4] Jeroen F. J. Laros,et al. Reproducibility of high-throughput mRNA and small RNA sequencing across laboratories , 2013, Nature Biotechnology.
[5] Mina Bissell,et al. Reproducibility: The risks of the replication drive , 2013, Nature.
[6] Fabian Prasser,et al. Enhancing Reuse of Data and Biological Material in Medical Research: From FAIR to FAIR-Health , 2018, Biopreservation and biobanking.
[7] Suzanne K. Linder,et al. A Survey on Data Reproducibility in Cancer Research Provides Insights into Our Limited Ability to Translate Findings from the Laboratory to the Clinic , 2013, PloS one.
[8] C. Begley,et al. Reproducibility: Six red flags for suspect work , 2013, Nature.
[9] I. Cockburn,et al. The Economics of Reproducibility in Preclinical Research , 2015, PLoS biology.
[10] F. Prinz,et al. Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.